Alt Title

Gender Differences in tPA Administration

Publication Date


Document Type

Conference Poster

First Advisor

Saravanan, Anitha


School of Nursing


As medicine and pharmacology advance through the years, new life-saving treatments are studied or discovered every day, and a medical emergency is no longer a death sentence. Even with conditions as serious as ischemic stroke, there is hope for survival and rehabilitation with the ‘clot-busting’ drug, tissue plasminogen activator, colloquially known as ‘tPA’. tPA is a thrombolytic agent, a substance that acts on fibrin in clots to dissolve them so they can no longer cause ischemia in blood vessels that results in a stroke. (Vega, 2022). tPA is an extremely effective treatment for ischemic stroke, demonstrated in 2013 by a 77% decrease in death from ischemic stroke in America since its approval in 1969 (Vega, 2022). However, not all patients are equally as likely to receive tPA in a manner effective enough for its full therapeutic and life-saving effects to be experienced. Despite women having a higher stroke rate than men on average (Gasbarrino et al, 2022), they are less likely to be triaged correctly or receive rapid administration of tPA for stroke when compared to their male counterparts (Bushnell et al, 2018). Due to this phenomenon, there is speculation on what correlation may exist between gender and quality of ischemic stroke treatment. This research provides in-depth analysis of literature on this subject, finding that both social and biological factors may contribute to reported differences in quality, speed, and efficacy of care between men and women, however, no direct determinants of this disparity have been identified to date.


2023 CURE Award Winner - 1st Place in Health and Human Services Posters


Northern Illinois University